Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants
Lv. Gubareva et al., Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants, ANTIM AG CH, 45(12), 2001, pp. 3403-3408
RWJ-270201 is a novel cyclopentane inhibitor of influenza A and B virus neu
raminidases (NAs). We compared the ability of RWJ-270201 to inhibit NA acti
vity of clinical influenza isolates and viruses with defined resistance mut
ations with that of zanamivir and oseltamivir carboxylate. In NA inhibition
assays with influenza A viruses, the median 50% inhibitory concentration (
IC50) of RWJ-270201 (approximately 0.34 nM) was comparable to that of oselt
amivir carboxylate (0.45 nM) but lower than that of zanamivir (0.95 nM). Fo
r influenza B virus isolates, the IC50 of RWJ-270201 (1.36 nM) was comparab
le to that of zanamivir (2.7 nM) and less than that of oseltamivir carboxyl
ate (8.5 nM). A zanamivir-resistant variant bearing a Glu119-to-Gly (Glu119
--> Gly) or Glu119 --> Ala substitution in an NA (N2) remained susceptible
to RWJ-270201 and oseltamivir carboxylate. However, a zanamivir-selected v
ariant with an Arg292 --> Lys substitution in an NA (N2) showed a moderate
level of resistance to RWJ-270201 (IC50 = 30 nM) and zanamivir (IC50 = 20 n
M) and a high level of resistance to oseltamivir carboxylate (IC50 > 3,000
nM). The zanamivir-resistant influenza B virus variant bearing an Arg152 --
> Lys substitution was resistant to each NA inhibitor (IC50 = 100 to 750 nM
). The oseltamivir-selected variant (N1) with the His274 --> Tyr substituti
on exhibited resistance to oseltamivir carboxylate (IC50 = 400 nM) and to R
WJ-270201 (IC50 = 40 nM) but retained full susceptibility to zanamivir (IC5
0 = 1.5 nM). Thus, drug-resistant variants with substitutions in framework
residues 119 or 274 can retain susceptibility to other NA inhibitors, where
as replacement of functional residue 152 or 292 leads to variable levels of
cross-resistance. We conclude that RWJ-270201 is a potent inhibitor of NAs
of wild-type and some zanamivir-resistant or oseltamivir-resistant influen
za A and B virus variants.